Bavarian Nordic A/S (BVNRY)
USD 9.23
(-0.22%)
USD 9.23
(-0.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 145.3 Million DKK | -91.74% |
| 2022 | 1.75 Billion DKK | 55.34% |
| 2021 | 1.13 Billion DKK | 140.94% |
| 2020 | 470.06 Million DKK | -74.34% |
| 2019 | 1.83 Billion DKK | 183.37% |
| 2018 | 646.49 Million DKK | 60.85% |
| 2017 | 401.91 Million DKK | 1161.89% |
| 2016 | 31.85 Million DKK | -4.33% |
| 2015 | 33.29 Million DKK | -5.36% |
| 2014 | 35.17 Million DKK | -56.2% |
| 2013 | 80.31 Million DKK | -10.14% |
| 2012 | 89.37 Million DKK | -9.86% |
| 2011 | 99.15 Million DKK | -7.16% |
| 2010 | 106.79 Million DKK | -10.11% |
| 2009 | 118.8 Million DKK | 0.0% |
| 2008 | - DKK | -100.0% |
| 2007 | 149.83 Million DKK | -25.35% |
| 2006 | 200.71 Million DKK | -21.81% |
| 2005 | 256.71 Million DKK | 39.7% |
| 2004 | 183.76 Million DKK | 28390.23% |
| 2003 | 645 Thousand DKK | 3.53% |
| 2002 | 623 Thousand DKK | 2495.83% |
| 2001 | 24 Thousand DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 133.59 Million DKK | -8.06% |
| 2024 Q2 | 124.61 Million DKK | -6.72% |
| 2023 FY | 145.3 Million DKK | -91.74% |
| 2023 Q3 | 106.09 Million DKK | -88.57% |
| 2023 Q2 | 928.13 Million DKK | 26.6% |
| 2023 Q1 | 733.11 Million DKK | -58.33% |
| 2023 Q4 | 145.3 Million DKK | 36.96% |
| 2022 Q1 | 973.02 Million DKK | -14.09% |
| 2022 FY | 1.75 Billion DKK | 55.34% |
| 2022 Q2 | 1.45 Billion DKK | 49.11% |
| 2022 Q4 | 1.75 Billion DKK | 15.0% |
| 2022 Q3 | 1.52 Billion DKK | 5.44% |
| 2021 Q4 | 1.13 Billion DKK | 21.47% |
| 2021 FY | 1.13 Billion DKK | 140.94% |
| 2021 Q1 | 485.26 Million DKK | 3.23% |
| 2021 Q2 | 787.34 Million DKK | 62.25% |
| 2021 Q3 | 932.41 Million DKK | 18.43% |
| 2020 Q4 | 470.06 Million DKK | -1.44% |
| 2020 Q1 | 485.17 Million DKK | -73.52% |
| 2020 FY | 470.06 Million DKK | -74.34% |
| 2020 Q2 | 482.14 Million DKK | -0.62% |
| 2020 Q3 | 476.94 Million DKK | -1.08% |
| 2019 Q3 | 461.35 Million DKK | -0.77% |
| 2019 FY | 1.83 Billion DKK | 183.37% |
| 2019 Q1 | 468.66 Million DKK | -27.51% |
| 2019 Q2 | 464.92 Million DKK | -0.8% |
| 2019 Q4 | 1.83 Billion DKK | 297.09% |
| 2018 FY | 646.49 Million DKK | 60.85% |
| 2018 Q4 | 646.49 Million DKK | -0.44% |
| 2018 Q3 | 649.36 Million DKK | -5.78% |
| 2018 Q2 | 689.16 Million DKK | 34.53% |
| 2018 Q1 | 512.26 Million DKK | 27.46% |
| 2017 Q3 | 30.25 Million DKK | -1.73% |
| 2017 Q2 | 30.78 Million DKK | -1.7% |
| 2017 Q1 | 31.31 Million DKK | -1.67% |
| 2017 Q4 | 401.91 Million DKK | 1228.55% |
| 2017 FY | 401.91 Million DKK | 1161.89% |
| 2016 Q2 | 32.31 Million DKK | -1.49% |
| 2016 Q1 | 32.8 Million DKK | -1.46% |
| 2016 FY | 31.85 Million DKK | -4.33% |
| 2016 Q4 | 31.85 Million DKK | -2.05% |
| 2016 Q3 | 32.51 Million DKK | 0.61% |
| 2015 Q1 | 34.7 Million DKK | -1.36% |
| 2015 Q3 | 33.77 Million DKK | -1.25% |
| 2015 Q4 | 33.29 Million DKK | -1.42% |
| 2015 FY | 33.29 Million DKK | -5.36% |
| 2015 Q2 | 34.2 Million DKK | -1.44% |
| 2014 FY | 35.17 Million DKK | -56.2% |
| 2014 Q2 | 76.4 Million DKK | -2.3% |
| 2014 Q1 | 78.2 Million DKK | -2.63% |
| 2014 Q4 | 35.17 Million DKK | -54.61% |
| 2014 Q3 | 77.5 Million DKK | 1.44% |
| 2013 Q4 | 80.31 Million DKK | -3.58% |
| 2013 Q3 | 83.3 Million DKK | -2.23% |
| 2013 Q2 | 85.2 Million DKK | -3.95% |
| 2013 Q1 | 88.7 Million DKK | -0.76% |
| 2013 FY | 80.31 Million DKK | -10.14% |
| 2012 FY | 89.37 Million DKK | -9.86% |
| 2012 Q3 | 92.6 Million DKK | -3.74% |
| 2012 Q2 | 96.2 Million DKK | 1.05% |
| 2012 Q1 | 95.2 Million DKK | -3.99% |
| 2012 Q4 | 89.37 Million DKK | -3.48% |
| 2011 Q3 | 224.6 Million DKK | 13.78% |
| 2011 Q4 | 99.15 Million DKK | -55.85% |
| 2011 FY | 99.15 Million DKK | -7.16% |
| 2011 Q2 | 197.4 Million DKK | 2.07% |
| 2011 Q1 | 193.4 Million DKK | 81.09% |
| 2010 Q3 | 209.2 Million DKK | 75.36% |
| 2010 Q4 | 106.79 Million DKK | -48.95% |
| 2010 FY | 106.79 Million DKK | -10.11% |
| 2010 Q1 | 117.6 Million DKK | -1.02% |
| 2010 Q2 | 119.3 Million DKK | 1.45% |
| 2009 Q4 | 118.8 Million DKK | 0.0% |
| 2009 FY | 118.8 Million DKK | 0.0% |
| 2008 FY | - DKK | -100.0% |
| 2007 FY | 149.83 Million DKK | -25.35% |
| 2006 FY | 200.71 Million DKK | -21.81% |
| 2005 FY | 256.71 Million DKK | 39.7% |
| 2004 FY | 183.76 Million DKK | 28390.23% |
| 2003 FY | 645 Thousand DKK | 3.53% |
| 2002 FY | 623 Thousand DKK | 2495.83% |
| 2001 FY | 24 Thousand DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -252.649% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -3425.073% |
| SQZ Biotechnologies Company | 27.47 Million USD | -428.929% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -235.006% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -388.129% |
| Mesoblast Limited | 118.7 Million USD | -22.411% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -15222.835% |
| Genus plc | 233.1 Million USD | 37.665% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -4858.456% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -10714.508% |
| Marizyme, Inc. | 18.71 Million USD | -676.29% |
| ContraFect Corporation | 2.88 Million USD | -4943.457% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -19273.6% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -107144.237% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -9946.331% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -6146.982% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -2467.92% |
| MultiCell Technologies, Inc. | 202.58 USD | -71725637.98% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -152.747% |
| EV Biologics, Inc. | 1.49 Million USD | -9620.816% |
| Q BioMed Inc. | 4.1 Million USD | -3435.345% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -338.966% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -22960.991% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -11728.933% |
| Biomind Labs Inc. | 735.54 Thousand USD | -19654.412% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 15.298% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -1017.966% |
| Skye Bioscience, Inc. | 4.61 Million USD | -3048.291% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -16261.659% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -102573.865% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -2374.873% |
| IMV Inc. | 28.88 Million USD | -403.055% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -564859.757% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -6333.901% |
| GB Sciences, Inc. | 1.75 Million USD | -8159.047% |
| Alpha Cognition Inc. | 1.22 Million USD | -11806.37% |
| HST Global, Inc. | 98.31 Thousand USD | -147686.287% |
| CSL Limited | 12.18 Billion USD | 98.807% |
| Halberd Corporation | 150 Thousand USD | -96768.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -14483.605% |
| Resverlogix Corp. | 6.49 Million USD | -2138.515% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -30329.738% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -56749.197% |
| argenx SE | 20 Million USD | -626.51% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -218.924% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -5264.265% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1420946.455% |
| Genscript Biotech Corporation | 417.73 Million USD | 65.217% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -72327.922% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -5959.997% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -63270.128% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -114.808% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -4701.481% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -40294.206% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -614.787% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -97645.099% |
| BioStem Technologies, Inc. | 4.71 Million USD | -2984.04% |
| ONE Bio Corp. | 19.71 Million USD | -637.012% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -57978.519% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -58319.91% |
| Agentix Corp. | 50 Thousand USD | -290504.0% |
| LadRx Corporation | 33.6 Thousand USD | -432269.22% |
| Cell Source, Inc. | 9.25 Million USD | -1470.124% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -19114.656% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -19114.656% |
| NovAccess Global Inc. | 2.19 Million USD | -6504.997% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -1954.374% |
| Itoco Inc. | 228.37 Thousand USD | -63523.745% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -68771.667% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -2815.954% |
| Kadimastem Ltd | 891.22 Thousand USD | -16203.609% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -36058.358% |
| CytoDyn Inc. | 30.07 Million USD | -383.116% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -29903.469% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -41196.927% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1758.091% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -118513.878% |
| Rebus Holdings, Inc. | 310 Thousand USD | -46771.613% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -2968.497% |
| International Stem Cell Corporation | 4.17 Million USD | -3377.788% |
| Bioxytran, Inc. | 1.92 Million USD | -7448.156% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -232707.268% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -6562.479% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -1647.258% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -1592.51% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -9241.303% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -54117.164% |
| Neutra Corp. | 54.15 Thousand USD | -268202.681% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -7840.0% |
| PureTech Health plc | 25.51 Million USD | -469.544% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -11768.887% |
| IXICO plc | 472.02 Thousand USD | -30682.822% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -837.372% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -133.368% |
| CSL Limited | 12.18 Billion USD | 98.807% |
| Cellectis S.A. | 92.77 Million USD | -56.615% |